Navigation Links
Ambit Biosciences Announces Third Quarter 2013 Operating Results
Date:11/7/2013

November 14, 2013.  Interested parties can access the replay by dialing 888-843-7419 or 630-652-3042 internationally and entering the conference number 35977176.

The conference call webcast is accessible through the "Investors & Media" section of the Ambit website at http://www.ambitbio.com.  An online replay will be available following the initial broadcast until Saturday, December 7, 2013.  Please visit Ambit's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Ambit Biosciences
Ambit is a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. Ambit's lead drug candidate, quizartinib (AC220), is a once-daily, orally-administered potent and selective, inhibitor of FMS-like tyrosine kinase-3 (FLT3) and is currently under clinical development in patients with relapsed/refractory acute myeloid leukemia (AML) and in newly diagnosed AML patients in combination with chemotherapy as well as maintenance following a hematopoietic stem cell transplantation (HSCT). In addition to quizartinib, Ambit's clinical pipeline includes AC410, an oral JAK2 inhibitor, and CEP-32496, a BRAF inhibitor licensed to Teva Pharmaceutical Industries Ltd. Ambit's preclinical portfolio includes a proprietary CSF1R inhibitor program.

Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with Ambit's expectations regarding future development and therapeutic potential of quizartinib and Ambit's other drug candidates, progress and timing o
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Announces Participation At 12th Annual BIO Investor Forum
2. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
5. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
6. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
7. Ambit Biosciences to Present at Two Upcoming Investor Conferences
8. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
9. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
10. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
11. Juneau Biosciences Names Dr. Dinesh Patel to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... 3, 2015 Forskare ... 2015 på  http://www.openinnovationinscience.at till det återkommande ... som hålls i Wien ... med internationella forskare och vetenskapsmän som genomfördes ... två största utmaningar bristen på incitament för ...
(Date:7/3/2015)... , July 3, 2015 ... den 22. september 2015 på  http://www.openinnovationinscience.at ... Science", der finder sted i ... nylig undersøgelse af internationale forskere og videnskabsmænd ... de to største udfordringer for sundhedsvidenskaben manglen ...
(Date:7/2/2015)... July 2, 2015  Spherix Incorporated (Nasdaq: SPEX ... and monetization of intellectual property, today announced a litigation ... Incorporated v. Verizon Services Corp. et al. , Case ... the Eastern District of Virginia , ... 2015 interpreting certain key claims in favor of the ...
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... ... development and manufacturing of surgical instruments in Orthopedics, announced today the acquisition of ... and the world's largest provider of surgical instruments to the Spine Industry. The ...
Breaking Biology Technology:Lansering av världens första program för öppen innovation för att utbilda forskare 2Lansering av världens första program för öppen innovation för att utbilda forskare 3Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 2Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 3Spherix Issues A Litigation Update 2Spherix Issues A Litigation Update 3In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3
... TORONTO, Aug. 27 Drug Royalty LP 2 ... Pharmaceuticals, Inc.,s (ENZN) worldwide,royalty interest in PEG-INTRON for ... in 2012 should certain royalty recognition levels be ... of,Hepatitis C and is marketed worldwide by Schering-Plough ...
... Notice is hereby,given that the 2007 Annual General Meeting ... (NASDQ:ROSG) (the "Company"), an,Israeli company, will be held at ... Tower, 47th floor, Tel Aviv, Israel on Monday, September ... purposes: 1. To approve the appointment of Kost, ...
... SAN CARLOS, Calif., Aug. 27 NeurogesX, Inc.,(Nasdaq: NGSX ... announced today that it is scheduled to present,at the 2007 ... Anthony DiTonno, President and Chief Executive Officer,and Stephen Ghiglieri, Chief ... Date: Thursday, September 6, 2007 ...
Cached Biology Technology:Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN) 2Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007 2NeurogesX to Present at BioCentury's NewsMakers in the Biotech Industry Conference 2NeurogesX to Present at BioCentury's NewsMakers in the Biotech Industry Conference 3
(Date:6/11/2015)... Va. , June 11, 2015 ... technology, announced today that its IdentityX Mobile Authentication ... (Fast IDentity Online) Alliance is an industry consortium ... open standards for simpler, stronger authentication.  In order ... must pass a rigorous series of tests that ...
(Date:6/9/2015)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... will be providing demonstrations of its iMedNet ... Information Association (DIA) Annual Meeting in Washington ... include previews of many exciting new enhancements that will ... 2015 Feature 1 Release. MedNet ...
(Date:6/8/2015)... , June 8, 2015  Trovagene, Inc. (NASDAQ: TROV ... clinical data featuring its Precision Cancer Monitoring SM platform ... Liquid Biopsies conference in San Diego, CA ... Precision Medicine Series: Integrating Clinical Genomics and Cancer Therapy ... June 13-16. "We continue to advance our ...
Breaking Biology News(10 mins):Daon's IdentityX Mobile Authentication Platform One of First Products to be Certified by FIDO Alliance 2MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 2MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 3Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 2Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 3Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 4
... HEIDELBERG, GERMANY, 20 OCTOBER 2011 EMBO today ... from 14 countries by awarding them life-long EMBO membership. ... commitment to research excellence and the exceptional achievements made ... the ranks of 1,500 of the best researchers in ...
... sativa has been exploited by humanity. Hemp seed oil ... its fibre is used in the production of fabrics. ... used medicinally for over 2700 years. The changes to the ... cannabis evolution, but one that has now been solved, thanks ...
... Wildfire, insect outbreaks and hurricanes destroy huge amounts ... carbon dioxide entering the atmosphere, but scientists are now ... their climate impact. Researchers conclude in a new ... of energy reflected back into space, is important in ...
Cached Biology News:46 outstanding life scientists elected to EMBO membership 2The cannabis genome: How hemp got high 2'Albedo effect' in forest disturbances can cause added warming, bonus cooling 2'Albedo effect' in forest disturbances can cause added warming, bonus cooling 3
... pLivSelect is a direct ... recombinant identification. Recombinant selection ... survival, eliminating the need ... This quick and inexpensive ...
... has been designed and created in order ... friendly genotyping analysis tool. We incorporated the ... into the software. Their main requirements were ... low acquisition cost. GeneMarker can perform ...
... through columns is a well-known separation technique ... applications are in DNA/RNA extraction in microbiology, ... purification in chemical or analytical laboratories. ... Genesis series instruments for smaller scales. The ...
... 3D structure visualization, phylogenetic tree building, sequence ... single application. Retrieve ... and filter them in real-time Organize ... searching, filtering and sorting Provides up-to-date ...
Biology Products: